Document is current

Article History

Received: 1 March 2021

Accepted: 28 April 2021

First Online: 11 May 2021

Declarations

:

: The study protocol was reviewed and approved by the Institutional Review Board (IRB) of the Aklilu Lemma Institute of Pathobiology, Addis Ababa University (Ref.: ALPB/IRB/006/2017/2018). District authorities, teachers, and children were informed about the survey procedures, objectives, and usefulness of the study. Written informed consent was sought from parents/guardians of children before data collection. Children who were not willing to participate or children whose parents did not sign the consent form were excluded from participation in the study. Children were informed that they could withdraw from the study at any time. Children infected with <i>S. mansoni</i> were treated with praziquantel (40 mg/body weight) by a health officer in accordance with WHO guidelines []. As triclabendazole was not included in the list of essential drugs in Ethiopia for treatment of human fascioliasis, children who were found positive for fascioliasis were referred to the health facilities. Those who were infected with other intestinal helminths were treated with appropriate antihelminthic drugs.

: Not applicable.

: The authors declare that they have no competing interests.